The Company focuses on all aspects of a treatment cycle – pre-operative planning, intra-operative guidance, post-operative evaluation, and long-term continued care – across many medical specialties. M2S features PEMS, a secure, web-based system with pre-measured morphology calculations, graphs, images, and other time-saving tools to accurately and efficiently monitor patient condition.
FreshTracks Capital is part of a syndicate of investors which completed an investment during Q3 2003 in MMS. The company was successfully sold to a division of AIG Altaris Health Partners in September 2005. Prior to this transaction, Cairn Cross, Managing Director for FreshTracks Capital, was an observer to M2S’ Board of Directors, and an ad hoc member of the board’s audit committee.Visit M2S / Medical Metrx